Shanghai Fosun Pharmaceutical : INDICATIVE ANNOUNCEMENT REGARDING THE 2019 THIRD EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 30 DECEMBER 2019
December 11, 2019 at 03:36 am EST
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02196)
INDICATIVE ANNOUNCEMENT
REGARDING THE 2019 THIRD EXTRAORDINARY GENERAL MEETING TO BE
HELD ON MONDAY, 30 DECEMBER 2019
This announcement is made pursuant to the disclosure requirement under the articles of association of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'').
The number of voting shares represented by the shareholders who intend to attend the 2019 third extraordinary general meeting of the Company to be held on Monday, 30 December 2019 (the ''EGM'') in person or by proxies is less than half of the total voting shares of the aforesaid meeting, calculated based on the written replies received by the Company twenty (20) days before the date of the EGM. In accordance with the Article 77 of the articles of association of the Company, details of the EGM are set out as follows:
DATE AND TIME OF THE EGM
The EGM will be held at 1:30 p.m. on Monday, 30 December 2019.
VENUE OF THE EGM
The EGM will be held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the People's Republic of China.
MATTERS TO BE CONSIDERED AT THE EGM
Please refer to the circular and notice of EGM of the Company dated 12 November 2019.
- 1 -
For holders of H shares of the Company, the form of proxy and the notarially certified power of attorney or other documents of authorisation (if any) must be delivered to the Company's Hong Kong share registrar for H shares, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 24 hours before the time appointed for the holding of the EGM or any adjournment thereof. Return of the form of proxy will not preclude any holder of H shares of the Company from attending the EGM and voting in person if such holder so wishes.
By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman
Shanghai, the People's Republic of China
11 December 2019
As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.
for identification purposes only
- 2 -
Attachments
Original document
Permalink
Disclaimer
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 11 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 December 2019 08:35:08 UTC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 
